Lightnews — Scholar-powered news

Norbert Kraut @norbertkraut.bsky.social · 8d

wien.orf.at/stories/3324...

Ein in Wien entwickeltes Medikament gegen eine spezielle Form von Lungenkrebs zeigt vielversprechende Ergebnisse. Nach Zulassungen in den USA, China und Japan könnte es bald auch in Europa verfügbar s...

wien.orf.at

2

Norbert Kraut @norbertkraut.bsky.social · Sep 7

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer | Science Translational Medicine
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer

The allele-agnostic mutant-KRAS inhibitor panKRASi inhibits the growth of murine and human pancreatic cancer and promotes antitumor immunity.

www.science.org

1 1 7

Reposted by Norbert Kraut

Elizabeth McKenna @elizsmckenna.bsky.social · Aug 8

ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...

2 3

Norbert Kraut @norbertkraut.bsky.social · Apr 24

Minisyposium on "Degraders and Glues" at #AACR25 co-chaired by Rima Al-awar and me this Tuesday, April 29, 2:30 pm CDT:
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social

www.abstractsonline.com/pp8/#!/20273...

2 6

Norbert Kraut @norbertkraut.bsky.social · Mar 9

Tackling Cancer through Global Team Science #cancergrandchallenges @theaacr.bsky.social aacrjournals.org/cancerdiscov...

Tackling Cancer through Global Team Science

Summary:. Here, we discuss the seven new challenges set by Cancer Grand Challenges that are currently open for creative applications. We invite the research community to assemble global, interdiscipli...

aacrjournals.org

1 5

Norbert Kraut @norbertkraut.bsky.social · Feb 15

aacrjournals.org/cancerdiscov...

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small Molecule Reactivator

Abstract. Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. Here, we describe...

aacrjournals.org

3

Norbert Kraut @norbertkraut.bsky.social · Feb 11

Starting soon @helloeacr.bsky.social

eacr.org/conference/b...

Introduction | EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway | The European Association for Cancer Research

eacr.org

1 4

Norbert Kraut @norbertkraut.bsky.social · Jan 13

Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhi...

aacrjournals.org

3 9

Norbert Kraut @norbertkraut.bsky.social · Dec 31

KRAS inhibitors: resistance drivers and combinatorial strategies: Trends in Cancer cell.com/trends/cance...

1 1 7

Norbert Kraut @norbertkraut.bsky.social · Dec 24

Hot off the press: Our work with #KRASmulti inhibitors suggests novel therapeutic concept for #cancers harboring #KRAS amplifications. Just published by our team at Boehringer Ingelheim in @theaacr.bsky.social journal Molecular Cancer Therapeutics.
aacrjournals.org/mct/article/...

1 3 11

Norbert Kraut @norbertkraut.bsky.social · Dec 11

Out now:
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer

www.tandfonline.com/doi/10.1080/...

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer

Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agent...

www.tandfonline.com

1 2

Norbert Kraut @norbertkraut.bsky.social · Dec 10

Thanks Anirban for including me

Norbert Kraut @norbertkraut.bsky.social · Nov 27

Great story @obenaufa.bsky.social and team. Congrats to a wonderful paper in @natureportfolio.bsky.social

Anna Obenauf @obenaufa.bsky.social · Nov 27

1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...

4